SCHEMBL6474331

SCHEMBL6474331

COc1ccc(-c2ccc(F)cc2)cc1COCCc1cccc(NS(=O)(=O)C(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERAP1 Q9NZ08 1/20 0.38
KDM1A O60341 1/20 0.38
IDO1 P14902 2/20 0.38
TDO2 P48775 1/20 0.38
FABP4 P15090 1/20 0.36
CYSLTR2 Q9NS75 1/20 0.36
CYSLTR1 Q9Y271 1/20 0.36
CA2 P00918 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CCNT1 O60563 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35
MGLL Q99685 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
POLB P06746 1/20 0.35
PTGS1 P23219 2/20 0.34
PTGS2 P35354 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480341 0.92 PPARA (0.39) ERAP1KDM1AIDO1TDO2FABP4
SCHEMBL6474945 0.87 KDM1A (0.39) KDM1ACYSLTR2CYSLTR1CA2MGLL
SCHEMBL6481112 0.87 KDM1A (0.41) KDM1ACYSLTR2CYSLTR1CA2MGLL
SCHEMBL6479703 0.85 KDM1A (0.45) KDM1ACYSLTR2CYSLTR1CA2MGLL
SCHEMBL6479679 0.85 KDM1A (0.42) KDM1ACYSLTR2CYSLTR1CA2LMNA
SCHEMBL6474487 0.84 PPARA (0.39) ERAP1KDM1AIDO1TDO2FABP4
SCHEMBL6482076 0.83 KDM1A (0.38) ERAP1KDM1ACYSLTR2CYSLTR1CA2
SCHEMBL6479426 0.81 KDM1A (0.43) KDM1ACYSLTR2CYSLTR1CA2PRMT6
SCHEMBL6474136 0.81 NAAA (0.40) ERAP1KDM1ACYSLTR2CYSLTR1CA2
SCHEMBL6474786 0.81 LTB4R (0.41) KDM1ACYSLTR2CYSLTR1CA2PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US claimed
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 ERAP1 1946/4885KDM1A 1124/4885IDO1 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.